Completed PHASE3 INTERVENTIONAL 3-arm NCT00595790

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis

Sponsor: Valneva Austria GmbH

Conditions Japanese Encephalitis

Interventions IC51

Updated 7 times since 2017 Last updated: Apr 9, 2014 Started: Sep 30, 2005 Primary completion: Feb 28, 2006 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00595790, this PHASE3 trial focuses on Japanese Encephalitis and remains completed. Sponsored by Valneva Austria GmbH, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Valneva Austria GmbH

Data source: Valneva Austria GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.